We are a digital healthcare company that develops regulated medical products and services using artificial intelligence.
Globally, chronic diseases are on the rise assisted by rapid urbanisation, sedentary lifestyles, changing diets, and rising obesity levels. By 2020, 50% of global health care expenditures, about $4 trillion, will be spent on three leading causes of death: cardiovascular diseases, cancer and respiratory diseases1.
In the UK, chronic diseases account for 50 per cent of all GP appointments, 64 per cent of all outpatient appointments, over 70 per cent of all inpatient bed days, and around 70% of NHS costs2.
Clinician led innovation is critical for managing chronic diseases but finding the right commercial model to bring these innovations to market at scale can be a real challenge.
1. Source: DELOITTE: 2017 Global Health Sciences Outlook Report
2. Source: The King’s Fund, Long Term Conditions and Multi-morbidity Report 2012
We are a digital healthcare company that works in partnership with world-class medical practitioners and healthcare providers to develop robust clinical evidence to the highest ethical and patient privacy standards to deliver AI powered regulated digital tools that improve health.
A great example of our principles being applied is the ground-breaking Strategic Research Agreement (SRA) that we signed with the University of Oxford (OU) and the Oxford University Hospitals NHS Foundation Trust (OUH).
The SRA will create a pathway for the production of world-class digital health products invented by OU and OUH and then commercialised globally by Drayson Health. This agreement will benefit patients across the NHS and overseas, and allows some of the profits to go back into the University of Oxford and the Oxford University Hospitals NHS Foundation Trust to fund more research and ultimately benefit more patients.
Winner 2017 Oxford Academic Health Science Network Best Public-Private Collaboration Award.
"This project is a very worthy winner of our 2017 Best Public-Private Collaboration award. It encapsulates everything this prize was set up to reward. The partnership across the research and innovation pathway has been at the heart of this clinically-led initiative from day one."
As part of this agreement we will commercialise three digital health products, SEND, GDm-health and EDGE. These digital health products have undergone clinical testing and validation involving over 100,000 patients and generated over 20 million data records to date.